MAP
CPRX

Moody Aldrich Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Moody Aldrich Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,334
Closed -$1.98M – 190
2025
Q3 		$1.98M Sell
100,334
-20,369
-17% -$419K 0.37% 99
2025
Q2 		$2.62M Sell
120,703
-61,868
-34% -$1.46M 0.51% 82
2025
Q1 		$4.43M Sell
182,571
-33,086
-15% -$745K 0.93% 43
2024
Q4 		$4.5M Sell
215,657
-60,990
-22% -$1.31M 0.83% 50
2024
Q3 		$5.5M Sell
276,647
-5,427
-2% -$101K 1% 38
2024
Q2 		$4.37M Sell
282,074
-18,877
-6% -$294K 0.85% 55
2024
Q1 		$4.8M Sell
300,951
-6,961
-2% -$105K 0.82% 53
2023
Q4 		$5.18M Buy
307,912
+34,400
+13% +$470K 0.93% 41
2023
Q3 		$3.2M Buy
273,512
+11,075
+4% +$148K 0.61% 68
2023
Q2 		$3.53M Buy
262,437
+60,355
+30% +$869K 0.69% 59
2023
Q1 		$3.35M Buy
+202,082
New +$3.33M 0.68% 64

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Moody Aldrich Partners's CPRX Position: Q4 2025 in Review

Moody Aldrich Partners sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 100,334 shares — an estimated $1.98M sold.

Moody Aldrich Partners first reported a position in CPRX in Q1 2023 and held it in 11 quarters. The position peaked at $5.5M in Q3 2024. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • Moody Aldrich Partners reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Moody Aldrich Partners sold 100,334 Catalyst Pharmaceutical shares in Q4 2025, an estimated $1.98M.
  • Moody Aldrich Partners first reported a position in Catalyst Pharmaceutical in Q1 2023 and held it in 11 quarters.
  • Moody Aldrich Partners's Catalyst Pharmaceutical position peaked at $5.5M in Q3 2024.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Moody Aldrich Partners's 13F filing for Q4 2025, filed 30 Jan 2026.